|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
D
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
Inflammatory response or allergic reaction |
|
Burning feeling at site of application |
|
contact dermatitis |
|
increased sensitivity of skin to sunlight |
|
itching |
|
oozing |
|
soreness or tenderness of skin |
|
Darkening of skin |
|
scaling |
|
watery eyes |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Hemorrhagic ulcerated tissues |
|
Pre-existing dermatoses, especially chloasma and rosacea |
|
|
ADULT DOSE:
|
|
Actinic (solar keratoses)-Topical, to the skin, as a 1% cream once or twice a day in a sufficient amount to cover the lesions. Usually the 1% strength is effective on the head, neck, and chest; 2 to 5% may be needed on the hands.
Superficial basal cell carcinomas-Topical, to the skin, as a 5% cream twice a day in a sufficient amount to cover the lesions, for at least three to six weeks, and possibly up to twelve weeks. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|